(CercleFinance.com) – Poxel announced on Thursday that it had obtained a new patent on PXL065 in the United States, which gives its experimental treatment against NASH additional protection until 2041.
The Lyon-based biopharmaceutical company says the patent issued by the US Patent and Trademark Office (PTO) relates to a new solid form of its compound.
This new patent also confers additional protection on the product, until 2041, with international coverage and a potential extension of five additional years.
Listed on the Paris Stock Exchange, the title Poxel did not react favorably to this announcement, showing a decline of around 1.2% at midday.
Results from the Phase II study of PXL065 in NASH are expected in the third quarter.